https://www.selleckchem.com/GSK-3.html https://www.selleckchem.com/GSK-3.html https://www.selleckchem.com/GSK-3.html Process in the Perfume Corona Monitoring (CoCoS) Study- a potential population-based cohort study. Synaptic atmosphere and also extrasynaptic glutamate indicators: The quest proceeds. Median time from P0 to P1 or death was 48days (range 8-248). Median paracentesis-free interval (P0-P1 or death) was 4.29-fold (95% CI 2.4-5.8) higher following a first dose of IP-bev compared with the time between paracenteses prior to study entry (P-1-P0). IP-bev was safe, active, and warrants further study as a palliative intervention for recurrent ascites in CR-EOC patients receiving best supportive care. IP-bev was safe, active, and warrants further study as a palliative intervention for recurrent ascites in CR-EOC patients receiving best supportive care. Report the results from a preplanned interim analysis of a phase III, double blind, randomized controlled study of ofranergene obadenovec (VB-111), a targeted anti-cancer gene therapy, in combination with paclitaxel in patients with platinum resistant ovarian cancer (PROC). The OVAL (NCT03398655) study is an on-going study where patients are randomly assigned in a 11 ratio to weekly paclitaxel 80 mg/m with VB-111 or placebo. link= The protocol specifies a pre-planned unblinded futility interim analysis of CA-125 response per GCIG criteria in the first 60 evaluable patients. The futility rule determined for this analysis was that the response rate of VB-111 must be greater than the response rate of placebo by at least 10% in order to continue the study. Coincident with the interim analysis, the blinded CA-125 response rate was estimated as a proportion of the first 60 evaluable patients with CA-125 response per GCIG criteria. Post-treatment fever is provided as a possible surrogate marker of VB-111 therapy actl as planned. No new safety signals were identified. At the time of the interim analysis, response rate findi